Thus, it is possible that compounds that activate the 5-HT2A receptor without activating the β-arrestin-2 pathway could help treat depression without causing unwanted hallucinogenic adverse effects.
Such compounds could offer numerous advantages over psychedelic drugs in treating depression and other psychiatric disorders.The researchers first screened the virtual library for THP derivatives that could bind a model of the 5-HT2A receptor.They initially synthesized 17 candidates with high docking scores and tested the ability of these compounds to activate the 5-HT2A receptor in laboratory cultured cells.
After testing these compounds, the researchers found four molecules that weakly activated the 5-HT2A receptor.These results suggest that the two novel compounds selectively activated the 5-HT2A receptor, with limited activation of the signaling pathway that could mediate the hallucinogenic effects of psychedelic substances.
In subsequent experiments, the researchers examined the behavioral effects of these compounds in mouse models.Psychedelic drugs like LSD produce hallucinogenic symptoms such as head twitches and increased locomotor activity in mice.
Significantly, these novel compounds produced antidepressant and anti-anxiety effects in mouse models.